Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2– breast cancer in the US

Key Points

• To evaluate the effectiveness and cost-effectiveness of genetic and genomic testing in guiding treatment for HR+/HER2– breast cancer.
• Comparison of testing strategies (full testing vs. no testing)
• Analysis of cost-effectiveness based on survival and quality-of-life outcomes
• Focus on the population with HR+/HER2– breast cancer
• Full testing strategy showed increased effectiveness compared to no testing
• Cost-effective outcomes were achieved with the full testing strategy
• Supporting improved survival and quality of life for women with breast cancer

Abstract